Diffuse cutaneous systemic sclerosis (dcSSc) Difficult to treat rheumatoid arthritis (D2TRA) research hub

A single-arm, open-label, multi-centre, phase I/II first-in-human study evaluating the safety and clinical activity of QEL-005, an autologous CAR T-regulatory cell therapy treatment targeting CD19, in patients with diffuse cutaneous systemic sclerosis (dcSSc) and in patients with difficult to treat rheumatoid arthritis (D2TRA).

This study is testing a new cell therapy called QEL-005 for people with specific types of severe rheumatoid arthritis or a skin condition called diffuse cutaneous systemic sclerosis. Researchers want to see if it's safe and if it helps improve these conditions.